Postpartum Endometritis: a Proposal for a Improved Patient Care and Reduced Costs

Total Page:16

File Type:pdf, Size:1020Kb

Postpartum Endometritis: a Proposal for a Improved Patient Care and Reduced Costs 5 The Canadian Journal of Hospital Pharmacy- Volume 48, No. 3, June 1995 181 11 ,t j PHARMACY PRACTICE ~ l. f e e Postpartum Endometritis: A Proposal for a Improved Patient Care and Reduced Costs Anita Kozyrskyj and Greg Ryan Guidelines for the prophylaxis and elective (low-risk) caesarean section most patients are healthy and able to treatment of postpartum endometritis patients also reduces the incidence of take medications orally, oral antibiotic have been in place in the Perinatal postpartum endometritis by at least therapy as a first line therapy was Unit at Mount Sinai Hospital since 58%. 2 entertained. Experience with oral the 1980s. During this time they have The prophylaxis of high-risk antibiotics as first line therapy for been continuously evaluated and caesarean section patients with one to postpartum endometritis was limited. revised in order to provide postpartum three doses of cefazolin lg starting at Amoxicillin, replacing intavenous patients with optimal pharmaco­ cord-clamping was the established ampicillin in the original guidelines, therapeutic care, while containing practice at Mount Sinai Hospital. was considered a possibility. treatment costs. Consistent with these During the time period July to However, the ideal oral agent would goals, the guidelines were again December 1993, patients who had not have activity against most of the revised with the additional objective received cefazolin prophylaxis at cord pathogens isolated in postpartum of introducing oral drug therapy as clamping and were subsequently endometritis, such as group B first line. In order to evaluate outcomes treated with intravenous antibiotics Streptococcus, Staphylococcus of the existing guidelines, antibiotic for postpartum endometritis repre­ epidermidis, Escherichia coli, Bac­ usage and costs were determined in sented 5% of all postpartum patients. teroides4 and especially Streptococcus postpartum patients for the time period Based on the antibiotic treatment costs f aecalis which can be selected out July to December 1993 using the drug for these patients, which include drug during cefazolin prophylaxis.5 utilization report capabilities of the acquisition, preparation, admini­ Oral amoxicillin-clavulanic acid Digimedics computer system. stration and laboratory monitoring represents such an agent. In a study Presented here are the questions asked costs, the annual treatment costs were by Fernandez et al, 73 postpartum during the revision process, the projected to be $27,500. Therefore, patients with mild endometritis, resultant changes to the guidelines cefazolin prophylaxis was extended defined as a temperature less than and the rationale for change. to all caesarean section patients with 38.5°C, were treated with either the aim of decreasing postpartum mor­ amoxicillin-clavulanic acid 500 mg Should prophylaxis be extended bidity and associated treatment costs. orally q8h or amoxicillin 500 mg/ to all caesarean section patients? metronidazole 500 mg orally q8h. For the most part, antibiotic Could oral antibiotic therapy be There was no difference between the prophylaxis of caesarean section has used as first line therapy in the groups in the number of days to been limited to high-risk caesarean treatment of mild to moderate defervescence or the infection rate. 6 section patients, for example those infections? Our guidelines were subsequently with prolonged premature rupture of Traditionally intravenous antibiotics changed to oral amoxicillin-clavulanic membranes. Prophylaxis of these had been used to treat postpartum acid for mild to moderate endometritis. patients reduces the incidence of endometritis, with ampicillin as the Oral amoxicillin was included as an postpartum endometritis by 50% .1 drug of choice, 3 followed by cefotetan alternative to amoxicillin-clavulanic However, a recently published meta­ or clindamycin and gentamicin if no acid. Oral clindamycin was reserved analysis showed that prophylaxis of response was seen in 24-48 hours. As for penicillin-allergic patients. Anita Kozyrskyj, B.Sc. Phm., was Supervisor, Perinatal Pharmacy Services, Mount Sinai Hospital, Toronto, Ontario. Ms. Kozyrskyj is now a Master's candidate, Dept. of Community Health, University of Manitoba. Greg Ryan, M.B., is Staff Obstetrician, Perinatal Unit, Mount Sinai Hospital, Toronto, Ontario. Address correspondence to: Anita Kozyrskyj, B.Sc.Phm., 505-44 The Promenade, Winnipeg, Manitoba, R3B 3H9. 182 The Canadian Journal of Hospital Pharmacy- Volume 48, No. 3, June 1995 T Should cefotetan be recommended Is it necessary to switch to oral Susceptibility of female pelvic pathogens F as a first line agent for severe therapy once the patient was afebrile to oral antibiotic agents in patients who develop postpartum endometritis. Am J endometritis and at what dose? or could therapy be stopped? Obstet Gynecol 1991; 164(5): 1383-6. From the Digimedics drug utilization In the past, all postpartum patients on 5. Stiver HG, Forward KR, Tyrrell DL, et reports it was revealed that the intravenous therapy who were afebrile al. Comparative cervical microflora majority of patients were treated with for 24-48 hours were switched to oral shifts after cefoxitin or cefazolin intravenous clindamycin and genta­ therapy. There was some evidence to prophylaxis against infection following caesarean section. Am J Obs Gyn micin. There was poor compliance indicate that switching to oral therapy 1984; 149(7):718-21. with the exisiting guidelines recom­ was not necessary in this population. 6. Fernandez H, Claquin C, Guibert M, et mending the use of ampicillin initially In two randomized studies, one of al. Suspected postpartum endometritis:a or the use of cefotetan as an alternative which was placebo controlled, the controlled clinical trial of single-agent to clindamycin and gentamicin. As efficacy rate was similar in groups antibiotic therapy with Amox-CA (Augumentin) vs ampicillin­ cefotetan has documented efficacy in switched to oral antibiotics and those metronidazole+-aminoglycoside. Eur J 7 8 postpartum endometritis , it was receiving no oral antibiotics after Obstet Gynecol Reprod Biology recommended as the treatment of patients were afebrile for 48-72 hours l 990;36:69-74. choice for severe infections because on intravenous therapy. 14,15 Only a 7. MacGregor R, Graziani A, Samuels P. of its convenient q 12h dosing. 50% compliance rate was documented Randomized, double-blind study of cefotetan and cefoxitin in post-caesarian Although mainly administered as a in mothers discharged on oral section endometritis. Am J Obstet 7 8 15 2 g dose in clinical trials, • as a beta­ antibiotics. Moreover, it has been Gynecol 1992; 167(1 ): 139-43. lactam, cefotetan exhibits time­ shown that breast-feeding mothers 8. Hemsell D, Wendel G, Gall S, et al. dependent, not concentration­ discharged on oral antibiotics Multicenter comparison of cefotetan and dependent bacterial killing. Higher discontinued the antibiotic or stopped cefoxitin in the treatment of acute obstetric and gynecologic infections. Am serum concentrations achieved with breast-feeding despite reassuring J Obstet Gynecol 1988;158:722-7. the 2 g dose do not result in greater advice that they could breastfeed while 9. Vogelman B, Gudmundsson S, LeggettJ, efficacy, provided that trough levels taking these antibiotics. 16 Therefore, et al. Correlation of antimicrobial exceed the MIC of the infecting discontinuation of therapy once the pharrnacokinetic parameters with organisms. 9 A serum trough concen­ patient was afebrile on intravenous therapeutic efficacy in an animal model. J Infect Dis 1988;1 58(4):831-47 tration of 7.4 mg/L is achieved 12 antibiotics was included as an option. 10. Martin C, Thomachot L, Albanes J. hours after a 1 g dose, greater than the Clinical Pharrnacokinetics of cefotetan. MIC of Bacteroides and other What were the outcomes of the Clin pharmacokinet 1994:26(4):249-58. susceptible bacteria. 10,11 Moreover, proposed changes? 11. Ward A, Richards D. Cefotetan, a review uterine and parametrial tissue levels The new guidelines were approved of its antibacterial activity, pharrnacokinetic properties and far exceed the MIC following a 1 g by the Antibiotic Subcommittee of therapeutic use. Drugs 1985;30:382-426. 12 dose. Therefore, it was also pro­ the Pharmacy and Therapeutics 12. Orr J, Sisson P, Barrett J, et al. posed that the cefotetan dose be Committee and updated in the annual Pharrnacokinetics and tissue kinetics of 1 modified from 2 g to 1 g q 12h. edition of the Hospital Drug gm cefotetan prophylaxis in adbominal Formulary in July 1994 (see Figure or vaginal hysterectomy. Am J Obstet Gynecol 1988; 158(3):742-3. What place in therapy do 1). Ongoing review of antibiotic 13. Bourget P, Fernandez H, Delouis C, et clindamycin and gentamicin have? utilization in postpartum patients and al. Pharrnacokinetics of tobramycin in Consistent with the previous guide­ monitoring of health outcomes, such pregnant women, safety and efficacy of a lines, clindamycin and gentamicin as the incidence of endometritis, was once-daily dose regimen. J Clin Pharm were reserved for patients with recommended to evaluate the new Therap 1991;16:167-76 W, M, M. guidelines. - 14. Hager Pascuzzi Vernon penicillin allergies or those not Efficacy of oral antibiotics following responding to cefotetan after 48-72 REFERENCES parenteral antibiotics for serious hours of therapy. Once daily genta­ 1. Monga M, Oshiro B. Puerperal infections in obstetrics and gynecology. micin dosing was proposed for these infections. Semin Perinatol Obstet Gynecol l 989;73:326-9 patients, following dosing recom­ 1993; 17(6):426-31. 15. Dinsmoor M, Newton E, Gibbs. A randomized, double-blind, placebo­ mendations used at Mount Sinai 2. Smail! F. Antibiotic prophylaxis and caesarian section. Br J Obs Gyn controlled trial of oral antibiotic therapy Hospital. As there was little experi­ 1992;99:789-90. following intravenous antibiotic therapy ence with the once daily regimen in 3. Pond DG, Bernstein PE, Love KR, et al. for postpartum endometritis. Obstet the postpartum population, 13 a pilot Comparison of ampicillin with Gynecol 1991;77:60-2 study of peak and 12-hour serum clindamycin plus gentamicin in the 16. Ito S, Koren G, Einarson T.
Recommended publications
  • Medical Review(S) Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................
    [Show full text]
  • Surgical Decolonization and Prophylaxis
    Surgical Decolonization and Prophylaxis SurgicalSurgical Decolonization Decolonization and Prophylaxis and Prophylaxis DECOLONIZATION DECOLONIZATION Nasal Screening Result Recommended Intervention Nasal Screening Result Recommended Intervention MRSA Negative • No decolonization required MSSAMRSA NegativeNegative • No decolonization required MSSA PositiveNegative • Intranasal mupirocin twice daily x 5 days MSSA Positive • Intranasal mupirocin twice daily x 5 days MRSA Positive • Intranasal mupirocin twice daily x 5 days, MRSA Positive AND• Intranasal mupirocin twice daily x 5 days, •ANDChlorhexidine bathing one day prior to surgery ANTIMICROBIAL• ChlorhexidinePROPHYLAXISbathing one day prior to surgery ANTIMICROBIAL PROPHYLAXIS CLINICAL CONSIDERATIONS • Preoperative dose-timing CLINICAL CONSIDERATIONS • PreoperativeWithin 60 minutesdose-timing of surgical incision WithinExceptions: 60 minutes vancomycin of surgicaland fluoroquinolones incision within 120 minutes of surgical incisionExceptions: vancomycin and fluoroquinolones within 120 minutes of surgical • Weightincision-based dosing • WeightCefazolin-based: 2 gm dosingfor patients <120 kg, and 3 gm for patients ≥120 kg Vancomycin:Cefazolin: 2 gm usefor ABW patients <120 kg, and 3 gm for patients ≥120 kg Gentamicin:Vancomycin: use use ABW ABW unless ABW is >120% of their IBW, in which case use AdjBWGentamicin:(see below use ABW for equation)unless ABW is >120% of their IBW, in which case use • DurationAdjBW of(see prophylaxis below for equation) • DurationA single of dose, prophylaxis
    [Show full text]
  • Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and Its Application
    Infect Dis Ther (2017) 6:57–67 DOI 10.1007/s40121-016-0144-8 REVIEW Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application Juwon Yim . Leah M. Molloy . Jason G. Newland Received: November 10, 2016 / Published online: December 30, 2016 Ó The Author(s) 2016. This article is published with open access at Springerlink.com ABSTRACT infections, CABP caused by penicillin- and ceftriaxone-resistant S. pneumoniae and Ceftaroline is a novel cephalosporin recently resistant Gram-positive infections that fail approved in children for treatment of acute first-line antimicrobial agents. However, bacterial skin and soft tissue infections and limited data are available on tolerability in community-acquired bacterial pneumonia neonates and infants younger than 2 months (CABP) caused by methicillin-resistant of age, and on pharmacokinetic characteristics Staphylococcus aureus, Streptococcus pneumoniae in children with chronic medical conditions and other susceptible bacteria. With a favorable and those with invasive, complicated tolerability profile and efficacy proven in infections. In this review, the microbiological pediatric patients and excellent in vitro profile of ceftaroline, its mechanism of action, activity against resistant Gram-positive and and pharmacokinetic profile will be presented. Gram-negative bacteria, ceftaroline may serve Additionally, clinical evidence for use in as a therapeutic option for polymicrobial pediatric patients and proposed place in therapy is discussed. Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 1F47F0601BB3F2DD. Keywords: Antibiotic resistance; Ceftaroline J. Yim (&) fosamil; Children; Methicillin-resistant St. John Hospital and Medical Center, Detroit, MI, Staphylococcus aureus; Streptococcus pneumoniae USA e-mail: [email protected] L.
    [Show full text]
  • Antimicrobial Surgical Prophylaxis
    Antimicrobial Surgical Prophylaxis The antimicrobial surgical prophylaxis protocol establishes evidence-based standards for surgical prophylaxis at The Nebraska Medical Center. The protocol was adapted from the recently published consensus guidelines from the American Society of Health-System Pharmacists (ASHP), Society for Healthcare Epidemiology of America (SHEA), Infectious Disease Society of America (IDSA), and the Surgical Infection Society (SIS) and customized to Nebraska Medicine with the input of the Antimicrobial Stewardship Program in concert with the various surgical groups at the institution. The protocol established here-in will be implemented via standard order sets utilized within One Chart. Routine surgical prophylaxis and current and future surgical order sets are expected to conform to this guidance. Antimicrobial Surgical Prophylaxis Initiation Optimal timing: Within 60 minutes before surgical incision o Exceptions: Fluoroquinolones and vancomycin (within 120 minutes before surgical incision) Successful prophylaxis necessitates that the antimicrobial agent achieve serum and tissue concentrations above the MIC for probable organisms associated with the specific procedure type at the time of incision as well as for the duration of the procedure. Renal Dose Adjustment Guidance The following table can be utilized to determine if adjustments are needed to antimicrobial surgical prophylaxis for both pre-op and post-op dosing. Table 1 Renal Dosage Adjustment Dosing Regimen with Dosing Regimen with CrCl Dosing Regimen with
    [Show full text]
  • Antimicrobial Stewardship Guidance
    Antimicrobial Stewardship Guidance Federal Bureau of Prisons Clinical Practice Guidelines March 2013 Clinical guidelines are made available to the public for informational purposes only. The Federal Bureau of Prisons (BOP) does not warrant these guidelines for any other purpose, and assumes no responsibility for any injury or damage resulting from the reliance thereof. Proper medical practice necessitates that all cases are evaluated on an individual basis and that treatment decisions are patient-specific. Consult the BOP Clinical Practice Guidelines Web page to determine the date of the most recent update to this document: http://www.bop.gov/news/medresources.jsp Federal Bureau of Prisons Antimicrobial Stewardship Guidance Clinical Practice Guidelines March 2013 Table of Contents 1. Purpose ............................................................................................................................................. 3 2. Introduction ...................................................................................................................................... 3 3. Antimicrobial Stewardship in the BOP............................................................................................ 4 4. General Guidance for Diagnosis and Identifying Infection ............................................................. 5 Diagnosis of Specific Infections ........................................................................................................ 6 Upper Respiratory Infections (not otherwise specified) ..............................................................................
    [Show full text]
  • Combination Therapy in Complicated Infections Due to S. Aureus
    Combination therapy in complicated infections due to S. aureus Alex Soriano ([email protected]) Service of Infectious Diseases Hospital Clínic of Barcelona ESCMIDUniversity of Barcelona eLibrary IDIBAPS © by author Staphylococcal dissemination to different organs 30 min after i.v. Infection (using a real-time Sureward, et al. imaging) Identification and treatment of the Staphylococcus aureus reservoir in vivo. J Exp Med 2016; 213: 1141-51 ESCMID eLibrary © by author Surewaard, et al. Identification and treatment of the Staphylococcus aureus reservoir in vivo. J Exp Med 2016; 213: 1141-51 ESCMID eLibrary Liver, Kupfer cell (purple ) © byS. aureus author(green) Surewaard, et al. Identification and treatment of the Staphylococcus aureus reservoir in vivo. J Exp Med 2016; 213: 1141-51 eradication Large cluster of S. from blood aureus inside of KC. Located in phagolysosomes ESCMID eLibrary © by author Surewaard, et al. Identification and treatment of the Staphylococcus aureus reservoir in vivo. J Exp Med 2016; 213: 1141-51 liver ESCMID eLibrary Vancosomes: vancomycin vancomycin (1h before ©or after by) authorwithin liposomes Surewaard, et al. Identification and treatment of the Staphylococcus aureus reservoir in vivo. J Exp Med 2016; 213: 1141-51 liver ESCMID eLibrary © by author Lehar S, et al. Novel antibody–antibiotic conjugate eliminates intracellular S. aureus. Nature 2015; 527: 1-19 ESCMID eLibrary © by author Lehar S, et al. Novel antibody–antibiotic conjugate eliminates intracellular S. aureus. Nature 2015; 527: 1-19 Animal model of S aureus bacteremia. Treatment started after 24h of the infection ESCMID eLibrary single dose © by author ESCMID CaseeLibrary #1 © by author Medical history: A 27 y-o man, without co-morbidity.
    [Show full text]
  • AMEG Categorisation of Antibiotics
    12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................
    [Show full text]
  • Penicillin Allergy Guidance Document
    Penicillin Allergy Guidance Document Key Points Background Careful evaluation of antibiotic allergy and prior tolerance history is essential to providing optimal treatment The true incidence of penicillin hypersensitivity amongst patients in the United States is less than 1% Alterations in antibiotic prescribing due to reported penicillin allergy has been shown to result in higher costs, increased risk of antibiotic resistance, and worse patient outcomes Cross-reactivity between truly penicillin allergic patients and later generation cephalosporins and/or carbapenems is rare Evaluation of Penicillin Allergy Obtain a detailed history of allergic reaction Classify the type and severity of the reaction paying particular attention to any IgE-mediated reactions (e.g., anaphylaxis, hives, angioedema, etc.) (Table 1) Evaluate prior tolerance of beta-lactam antibiotics utilizing patient interview or the electronic medical record Recommendations for Challenging Penicillin Allergic Patients See Figure 1 Follow-Up Document tolerance or intolerance in the patient’s allergy history Consider referring to allergy clinic for skin testing Created July 2017 by Macey Wolfe, PharmD; John Schoen, PharmD, BCPS; Scott Bergman, PharmD, BCPS; Sara May, MD; and Trevor Van Schooneveld, MD, FACP Disclaimer: This resource is intended for non-commercial educational and quality improvement purposes. Outside entities may utilize for these purposes, but must acknowledge the source. The guidance is intended to assist practitioners in managing a clinical situation but is not mandatory. The interprofessional group of authors have made considerable efforts to ensure the information upon which they are based is accurate and up to date. Any treatments have some inherent risk. Recommendations are meant to improve quality of patient care yet should not replace clinical judgment.
    [Show full text]
  • Antibiotic Review
    8/28/19 Disclosure 2 E. Monee’ Carter-Griffin DNP, MA, RN, ACNP-BC Antibiotic has no financial relationships with commercial Review interests to disclose. Any unlaBeled and/or E. Monee’ Carter-Griffin, DNP, MA, RN, ACNP-BC unapproved uses of drugs or products will Be Associate Chair for Advanced Practice Nursing disclosed. University of Texas at Arlington, College of Nursing & Health Innovation Dallas Pulmonary & Critical Care, PA • Identify the general characteristics of • SusceptiBility à determine which antibiotics. antibiotics a bacteria is sensitive to • Discuss the mechanism of action, • à pharmacokinetics, and spectrum of activity MIC lowest concentration of drug that inhiBits growth of the Bacteria for the most common antiBiotic drug classes. Antibiotic Objectives • Identify commonly prescriBed antiBiotics • Trough à lowest concentration of within the drug classes including dosage Lingo drug in bloodstream range and indication for prescribing. – Collect prior to administration of • Identify special considerations for specific drug antibiotics and/or drug classes. • Peak à highest concentration of • Practice appropriate prescriBing for common drug in bloodstream bacterial infections. • Review Basic antiBiotic stewardship 3 4 principles. • Penicillins • Bactericidal or bacteriostatic • Cephalosporins • Narrow or Broad spectrum • Carbapenems General • Can elicit allergic responses Antibiotic • MonoBactam Characteristics • Affect normal Body flora Drug Classes • Macrolides • Fluoroquinolones • Sulfonamides • Tetracyclines 5 6 1 8/28/19 • Penicillins – Natural penicillins 8 – Aminopenicillins Penicillins Penicillins – Anti-staphylococcal penicillins • Mechanism of action àbactericidal à – Anti-pseudomonal penicillins interrupts cell wall synthesis 7 • Pharmacokinetics • Spectrum of Activity – Gram positive organisms Natural – Penicillin G à mostly given IM, But Natural • Streptococcus species (e.g. S. Penicillins one variation can Be given IV Penicillins pyogenes) • Poorly aBsorBed via PO • Some enterococcus species (e.g.
    [Show full text]
  • Computational Antibiotics Book
    Andrew V DeLong, Jared C Harris, Brittany S Larcart, Chandler B Massey, Chelsie D Northcutt, Somuayiro N Nwokike, Oscar A Otieno, Harsh M Patel, Mehulkumar P Patel, Pratik Pravin Patel, Eugene I Rowell, Brandon M Rush, Marc-Edwin G Saint-Louis, Amy M Vardeman, Felicia N Woods, Giso Abadi, Thomas J. Manning Computational Antibiotics Valdosta State University is located in South Georgia. Computational Antibiotics Index • Computational Details and Website Access (p. 8) • Acknowledgements (p. 9) • Dedications (p. 11) • Antibiotic Historical Introduction (p. 13) Introduction to Antibiotic groups • Penicillin’s (p. 21) • Carbapenems (p. 22) • Oxazolidines (p. 23) • Rifamycin (p. 24) • Lincosamides (p. 25) • Quinolones (p. 26) • Polypeptides antibiotics (p. 27) • Glycopeptide Antibiotics (p. 28) • Sulfonamides (p. 29) • Lipoglycopeptides (p. 30) • First Generation Cephalosporins (p. 31) • Cephalosporin Third Generation (p. 32) • Fourth-Generation Cephalosporins (p. 33) • Fifth Generation Cephalosporin’s (p. 34) • Tetracycline antibiotics (p. 35) Computational Antibiotics Antibiotics Covered (in alphabetical order) Amikacin (p. 36) Cefempidone (p. 98) Ceftizoxime (p. 159) Amoxicillin (p. 38) Cefepime (p. 100) Ceftobiprole (p. 161) Ampicillin (p. 40) Cefetamet (p. 102) Ceftoxide (p. 163) Arsphenamine (p. 42) Cefetrizole (p. 104) Ceftriaxone (p. 165) Azithromycin (p.44) Cefivitril (p. 106) Cefuracetime (p. 167) Aziocillin (p. 46) Cefixime (p. 108) Cefuroxime (p. 169) Aztreonam (p.48) Cefmatilen ( p. 110) Cefuzonam (p. 171) Bacampicillin (p. 50) Cefmetazole (p. 112) Cefalexin (p. 173) Bacitracin (p. 52) Cefodizime (p. 114) Chloramphenicol (p.175) Balofloxacin (p. 54) Cefonicid (p. 116) Cilastatin (p. 177) Carbenicillin (p. 56) Cefoperazone (p. 118) Ciprofloxacin (p. 179) Cefacetrile (p. 58) Cefoselis (p. 120) Clarithromycin (p. 181) Cefaclor (p.
    [Show full text]
  • Staphylococcus Aureus Bloodstream Infection Treatment Guideline
    Staphylococcus aureus Bloodstream Infection Treatment Guideline Purpose: To provide a framework for the evaluation and management patients with Methicillin- Susceptible (MSSA) and Methicillin-Resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI). The recommendations below are guidelines for care and are not meant to replace clinical judgment. The initial page includes a brief version of the guidance followed by a more detailed discussion of the recommendations with supporting evidence. Also included is an algorithm describing management of patients with blood cultures positive for gram-positive cocci. Brief Key Points: 1. Don’t ignore it – Staphylococcus aureus isolated from a blood culture is never a contaminant. All patients with S. aureus in their blood should be treated with appropriate antibiotics and evaluated for a source of infection. 2. Control the source a. Removing infected catheters and prosthetic devices – Retention of infected central venous catheters and prosthetic devices in the setting of S. aureus bacteremia (SAB) has been associated with prolonged bacteremia, treatment failure and death. These should be removed if medically possible. i. Retention of prosthetic material is associated with an increased likelihood of SAB relapse and removal should be considered even if not clearly infected b. Evaluate for metastatic infections (endocarditis, osteomyelitis, abscesses, etc.) – Metastatic infections and endocarditis are quite common in SAB (11-31% patients with SAB have endocarditis). i. All patients should have a thorough history taken and exam performed with any new complaint evaluated for possible metastatic infection. ii. Echocardiograms should be strongly considered for all patients with SAB iii. All patients with a prosthetic valve, pacemaker/ICD present, or persistent bacteremia (follow up blood cultures positive) should undergo a transesophageal echocardiogram 3.
    [Show full text]
  • Management of Penicillin and Beta-Lactam Allergy
    Management of Penicillin and Beta-Lactam Allergy (NB Provincial Health Authorities Anti-Infective Stewardship Committee, September 2017) Key Points • Beta-lactams are generally safe; allergic and adverse drug reactions are over diagnosed and over reported • Nonpruritic, nonurticarial rashes occur in up to 10% of patients receiving penicillins. These rashes are usually not allergic and are not a contraindication to the use of a different beta-lactam • The frequently cited risk of 8 to 10% cross-reactivity between penicillins and cephalosporins is an overestimate based on studies from the 1970’s that are now considered flawed • Expect new intolerances (i.e. any allergy or adverse reaction reported in a drug allergy field) to be reported after 0.5 to 4% of all antimicrobial courses depending on the gender and specific antimicrobial. Expect a higher incidence of new intolerances in patients with three or more prior medication intolerances1 • For type-1 immediate hypersensitivity reactions (IgE-mediated), cross-reactivity among penicillins (table 1) is expected due to similar core structure and/or major/minor antigenic determinants, use not recommended without desensitization • For type-1 immediate hypersensitivity reactions, cross-reactivity between penicillins (table 1) and cephalosporins is due to similarities in the side chains; risk of cross-reactivity will only be significant between penicillins and cephalosporins with similar side chains • Only type-1 immediate hypersensitivity to a penicillin manifesting as anaphylaxis, bronchospasm,
    [Show full text]